anthrax toxins
Recently Published Documents


TOTAL DOCUMENTS

64
(FIVE YEARS 2)

H-INDEX

22
(FIVE YEARS 1)

Author(s):  
Nicole J. Yang ◽  
Jörg Isensee ◽  
Dylan V. Neel ◽  
Andreza U. Quadros ◽  
Han-Xiong Bear Zhang ◽  
...  

2020 ◽  
Vol 17 (12) ◽  
pp. 1516-1530
Author(s):  
Nousheen Bibi ◽  
Sehraiz Razzaq ◽  
Faisal Nouroz ◽  
Farhat Amin ◽  
Ambreen Shahnaz ◽  
...  

Background: The intentional dissemination of the “anthrax letter” led the researchers to increase their efforts towards the development of medical countermeasures against anthrax bioterrorism. A virulent strain of Bacillus anthracis secretes deadly three protein exotoxin (protective antigen, lethal factor and edema factor) that is the causative agent of anthrax and considered as serious biological weapons. Objective: Due to limited existing therapeutics options, there is still an insecure situation to combat anthrax. This prompted us to design a multifunctional inhibitor instead of a traditional one that competes simultaneously with the Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF) for their binding sites. Methods: We integrated a pharmacophore modeling approach with the virtual screening and molecular docking analysis in the context of unique structural characteristics of deadly anthrax toxins. Results: Initially, we screened 56,000 natural compounds against designed pharmacophore consensus that returned 351 hits. Out of these initial screening hits, only 100 compounds passed out through Lipinski filter that comprised of 12 chemically relevant clusters. By exclusion of duplicate and based on their fit score in each cluster, 15 unique compounds were selected for detailed study. Putative multifunctional compounds subjected to deep structural analysis in the milieu of anthrax toxins binding pockets to gauge critical structural crunch. Conclusion: Our integrative approach provides a novel therapeutic window to develop a small molecular inhibitor that simultaneously targets three components of anthrax deadly toxin at the molecular level to elicit the desired biological process.


2020 ◽  
Vol 8 (8) ◽  
pp. 1103
Author(s):  
Jean-Nicolas Tournier ◽  
Clémence Rougeaux

Anthrax toxins are produced by Bacillus anthracis throughout infection and shape the physiopathogenesis of the disease. They are produced in low quantities but are highly efficient. They have thus been long ignored, but recent biochemical methods have improved our knowledge in animal models. This article reviews the various methods that have been used and how they could be applied to clinical diagnosis.


2020 ◽  
Author(s):  
Nicole J. Yang ◽  
Jörg Isensee ◽  
Dylan Neel ◽  
Sai Man Liu ◽  
Han Xiong Bear Zhang ◽  
...  

ABSTRACTBacterial toxins are able to act on neurons to modulate signaling and function. Here, we find that nociceptive sensory neurons that mediate pain are enriched in the receptor for anthrax toxins, ANTXR2. Anthrax Edema Toxin (ET) induced cAMP and PKA signaling in Nav1.8+ nociceptive neurons and modulated pain in vivo. Peripherally administered ET mediated mechanical allodynia in naïve mice and during B. anthracis infection. Intrathecally administered ET produced analgesic effects, potently blocking pain-like behaviors in multiple mouse models of inflammatory and chronic neuropathic pain. Nociceptor-specific ablation of ANTXR2 attenuated ET-induced signaling and analgesia. Modified anthrax toxin successfully delivered exogenous protein cargo into nociceptive neurons, illustrating utility of the anthrax toxin system as a molecular platform to target pain. ET further induced signaling in human iPSC-derived sensory neurons. Our findings highlight novel interactions between a bacterial toxin and nociceptors that may be utilized for developing new pain therapeutics.SUMMARYANTXR2 expression on nociceptive neurons allows selective targeting and modulation of pain by native and engineered anthrax toxins.


2020 ◽  
pp. 1094-1102
Author(s):  
Arthur E. Brown

Anthrax is primarily a disease of herbivorous mammals, caused by the Gram-positive rod Bacillus anthracis, which causes human infection when its spores enter the body, most commonly from handling infected animals or animal products. The disease occurs in most countries of the world, but is only sporadic where the condition is controlled in livestock by vaccination programmes. Anthrax is a leading agent of biological warfare. After entry into the body, anthrax spores are phagocytosed by macrophages and carried to regional lymph nodes, where they germinate to produce vegetative bacilli that enter the bloodstream. These produce anthrax toxins, which have effects including impairment of cellular water homeostasis and of many intracellular signalling pathways.


F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1415
Author(s):  
Oksana A. Sergeeva ◽  
F. Gisou van der Goot

The anthrax toxin receptors—capillary morphogenesis gene 2 (CMG2) and tumor endothelial marker 8 (TEM8)—were identified almost 20 years ago, although few studies have moved beyond their roles as receptors for the anthrax toxins to address their physiological functions. In the last few years, insight into their endogenous roles has come from two rare diseases: hyaline fibromatosis syndrome, caused by mutations in CMG2, and growth retardation, alopecia, pseudo-anodontia, and optic atrophy (GAPO) syndrome, caused by loss-of-function mutations in TEM8. Although CMG2 and TEM8 are highly homologous at the protein level, the difference in disease symptoms points to variations in the physiological roles of the two anthrax receptors. Here, we focus on the similarities between these receptors in their ability to regulate extracellular matrix homeostasis, angiogenesis, cell migration, and skin elasticity. In this way, we shed light on how mutations in these two related proteins cause such seemingly different diseases and we highlight the existing knowledge gaps that could form the focus of future studies.


2019 ◽  
Vol 41 (1) ◽  
pp. 25-31
Author(s):  
Masoud Abdous ◽  
Sadegh Hasannia ◽  
Ali Hatef Salmanian ◽  
Seyed Shahryar Arab ◽  
Abbas Shali ◽  
...  

ACS Sensors ◽  
2018 ◽  
Vol 3 (11) ◽  
pp. 2303-2310 ◽  
Author(s):  
Jennifer H. Granger ◽  
Marc D. Porter

Sign in / Sign up

Export Citation Format

Share Document